Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH)
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Sponsor: Gilead Sciences
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Gilead Sciences
Other Liver Fibrosis Due to NASH trials with similar outcome
A PHASE2 clinical study on Liver Fibrosis Due to NASH, this trial is terminated or withdrawn. The trial is conducted by Gilead Sciences and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .